Jacobs Levy Equity Management
ACAD icon

Jacobs Levy Equity Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Jacobs Levy Equity Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.18M Sell
142,716
-228,331
-62% -$5.46M 0.01% 504
2025
Q4 		$9.91M Sell
371,047
-371,031
-50% -$8.87M 0.04% 305
2025
Q3 		$15.8M Sell
742,078
-19,106
-3% -$452K 0.06% 230
2025
Q2 		$16.4M Sell
761,184
-1,216,248
-62% -$22.6M 0.06% 236
2025
Q1 		$32.8M Buy
1,977,432
+838,728
+74% +$15.2M 0.13% 168
2024
Q4 		$20.9M Sell
1,138,704
-72,610
-6% -$1.17M 0.07% 216
2024
Q3 		$18.6M Sell
1,211,314
-143,688
-11% -$2.4M 0.07% 245
2024
Q2 		$22M Buy
+1,355,002
New +$21.9M 0.09% 203
2024
Q1 		– Sell
-105,396
Closed -$3.3M – 930
2023
Q4 		$3.3M Sell
105,396
-1,319,007
-93% -$31.5M 0.02% 511
2023
Q3 		$29.7M Sell
1,424,403
-411,615
-22% -$11.2M 0.18% 134
2023
Q2 		$44M Sell
1,836,018
-46,335
-2% -$1.03M 0.25% 99
2023
Q1 		$35.4M Buy
1,882,353
+243,170
+15% +$4.63M 0.22% 122
2022
Q4 		$26.1M Buy
1,639,183
+552,681
+51% +$8.64M 0.18% 156
2022
Q3 		$17.8M Buy
+1,086,502
New +$17.6M 0.14% 185
2022
Q2 		– Sell
-589,726
Closed -$14.3M – 985
2022
Q1 		$14.3M Buy
589,726
+48,664
+9% +$1.18M 0.1% 237
2021
Q4 		$12.6M Buy
541,062
+30,834
+6% +$620K 0.08% 263
2021
Q3 		$8.47M Buy
+510,228
New +$9.84M 0.06% 333
2021
Q2 		– Sell
-18,845
Closed -$486K – 1018
2021
Q1 		$486K Buy
+18,845
New +$830K ﹤0.01% 863

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jacobs Levy Equity Management's ACAD Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Acadia Pharmaceuticals (ACAD) stake by 62% in Q1 2026, selling an estimated $5.46M and leaving 142,716 shares worth $3.18M. The position accounts for 0.01% of the portfolio, ranked #504.

Jacobs Levy Equity Management first reported a position in ACAD in Q1 2021 and has held it in 18 quarters since. The position peaked at $44M in Q2 2023. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Jacobs Levy Equity Management held 142,716 shares of Acadia Pharmaceuticals worth $3.18M as of Q1 2026.
  • Jacobs Levy Equity Management sold 228,331 Acadia Pharmaceuticals shares in Q1 2026, an estimated $5.46M.
  • Acadia Pharmaceuticals made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #504 holding.
  • Jacobs Levy Equity Management first reported a position in Acadia Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
  • Jacobs Levy Equity Management's Acadia Pharmaceuticals position peaked at $44M in Q2 2023.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.